Intan Nureslyna Samsudin

Intan Nureslyna Samsudin

Auto-generated profile, based on publicly available information

Intan Nureslyna Samsudin

Department of Pathology, Faculty of Medicine & Health Sciences, Universiti Putra Malaysia , Selangor

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Osteoporosis and Sarcopenia
Verified
Journal Article
Open access
SYSwan Yeap
Swan Yeap
MFM.F.R. Nur Fazirah
M.F.R. Nur Fazirah
CAC. Nur Aisyah
C. Nur Aisyah
SSSiti Yazmin Zahari Sham
Siti Yazmin Zahari Sham
ISIntan Nureslyna Samsudin
Intan Nureslyna Samsudin
SCSiew Pheng Chan
Siew Pheng Chan
Following an osteoporotic fracture, pharmacological treatment is recommended to increase bone mineral density and prevent future fractures. However, the rate of starting treatment after an osteoporotic hip fracture remains low. The objective of this study was to survey the treatment rate following a low-trauma hip fracture at a tertiary private hospital in Malaysia over a period of 5 years. The computerised hospital discharge records were searched using the terms "hip," "femur," "femoral," "trochanteric," "fracture," or "total hip replacement" for all patients over the age of 50, admitted between 2010 and 2014. The medical charts were obtained and manually searched for demographic data and treatment information. Hip operations done for non-low-trauma-related fracture and arthritis were excluded. Three hundred seventy patients over the age of 50 years were admitted with a hip fracture, of which 258 (69.7%) were low trauma, presumed osteoporotic, hip fractures. The median age was 79.0 years (interquartile range [IQR], 12.0). Following a hip fracture, 36.8% (95 of 258) of the patients received treatment, but out of these, 24.2% (23 of 95) were on calcium/vitamin D only. The median duration of treatment was 1 month (IQR, 2.5). In 2010, 56.7% of the patients received treatment, significantly more than subsequent years 2011-2014, where approximately only 30% received treatment. Following a low-trauma hip fracture, approximately 72% of patients were not started on active antiosteoporosis therapy. Of those who were, the median duration of treatment was 1 month. This represents a missed opportunity for the prevention of future fractures.

1 December 2020 in Osteoporosis and Sarcopenia
Verified
Journal Article
Open access
SYSwan Yeap
Swan Yeap
STSubashini C. Thambiah
Subashini C. Thambiah
ISIntan Nureslyna Samsudin
Intan Nureslyna Samsudin
GAGeeta Appannah
Geeta Appannah
NZNurunnaim Zainuddin
Nurunnaim Zainuddin
FHFen Lee Hew
Fen Lee Hew
To determine the prevalence of osteopenia (OPe) and osteoporosis (OP) in an urban adult population in Malaysia, and to compare the change in the prevalence when using a Caucasian compared to an Asian reference range. A cross-sectional random sample of the population aged between 45 and 90 years from the state of Selangor, Malaysia, was invited to attend a bone health check-up. Participants with diseases known to affect bone metabolism or who were on treatment for OP were excluded. Bone mineral density was measured using dual energy X-ray absorptiometry. Based on the World Health Organization definitions, the prevalence of OPe and OP was calculated using the Asian and Caucasian T-scores. A total of 342 subjects (222 females, 120 males), with a mean age of 59.68 (standard deviation: 8.89) years, who fulfilled the study criteria were assessed. Based on the Asian reference range, there were 140 (40.9%) subjects with OPe and 48 (14.0%) with OP. On applying the Caucasian reference range, there were 152 (44.4%) subjects with OPe and 79 (23.1%) with OP, with significant increases in males, females, and Chinese ethnic groups. Overall, 75 (21.9%) of subjects had a change in their diagnostic status. T-scores were consistently lower when the Caucasian reference range was used. In a healthy urban Malaysian population, the prevalence of OP is 14.0% and OPe is 40.9%. Application of a Caucasian reference range significantly increased the number of subjects with OP and may potentially lead to over-treatment.

2 May 2018 in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
Verified
Journal Article
Closed access
ISIntan Nureslyna Samsudin
Intan Nureslyna Samsudin
MPMichael M Page
Michael M Page
KHKirsten Hoad
Kirsten Hoad
PCPaul Chubb
Paul Chubb
MGMelissa Gillett
Melissa Gillett
SVSamuel Vasikaran
Samuel Vasikaran
Background: Plasma free metanephrines (PFM) or urinary fractionated metanephrines (UFM) are the preferred biochemical tests for the diagnosis of phaeochromocytoma and paraganglioma (PPGL). Borderline increased results should be followed up to either exclude or confirm diagnosis. Methods: We extracted all PFM and UFM results reported by our laboratory over a 6-month period from the laboratory information system. We categorised patients with borderline increased results according to whether follow-up testing had been performed as suggested in the initial laboratory report. Questionnaires were then sent to all requesting doctors and medical notes reviewed where available. Results: Two hundred and four patients with borderline increased PFM or UFM were identified. Sixty-five (38.5%) of 169 patients with borderline increased PFM had a repeat test out of which 36 were normal and 29 did not normalize. Of 35 patients with borderline increased UFM, 17 (48.6%) had subsequent PFM measurement out of which 15 were normal. Questionnaires were returned for 106 (52%) of patients. Of these, the most frequent indication for testing was hypertension (n=50); 15 patients had an incidental adrenal mass and two of these patients were diagnosed with a phaeochromocytoma. Conclusion: Only thirty-eight percent of patients with borderline increased PFM had a repeat PFM measurement. This was not significantly higher when compared to the 28% in a previous audit that we reported in 2010 (P=0.10). Forty nine percent of patients with a borderline increased UFM had a repeat UFM or PFM measurement. There remains a substantial possibility of missed detection of PPGL.

1 August 2016
Verified
Journal Article
Closed access
STSubashini C. Thambiah
Subashini C. Thambiah
ISIntan Nureslyna Samsudin
Intan Nureslyna Samsudin
EGElizabeth George
Elizabeth George
SSSiti Yazmin Zahari Sham
Siti Yazmin Zahari Sham
HLHuey Ming Lee
Huey Ming Lee
MMMasni Mohamad
Masni Mohamad

22 July 2019 in Biomarkers
Verified
Journal Article
Closed access
STSubashini C. Thambiah
Subashini C. Thambiah
MSMeor Fairuz Rizal Meor Anuar Shuhaili
Meor Fairuz Rizal Meor Anuar Shuhaili
BCBoon-How Chew
Boon-How Chew
ISIntan Nureslyna Samsudin
Intan Nureslyna Samsudin
HRHejar Abdul Rahman
Hejar Abdul Rahman
ZAZalinah Ahmad
Zalinah Ahmad
Introduction: Statin, the first-line treatment for dyslipidaemia, may have suboptimal adherence due to its associated muscle adverse events. This data however, remains limited. Aim: To determine the association of serum creatine kinase(CK) and SLCO1B1 rs4363657 polymorphism with statin-associated muscle adverse events(SAMAE) among dyslipidaemia participants. Methods: This was a prospective cohort study at government health clinics involving newly diagnosed adults with dyslipidaemia. SAMAE were recorded based on the patient’s complaint after a month on statin. CK was taken at baseline and follow-up. Genetic profiling was performed for SLCO1B1 rs4363657 polymorphism. Results: Among 118 participants, majority were Malay(72%) males(61%) with a mean age of 49 ± 12.2 years old and prescribed lovastatin(61.9). There was a significant association between statin types(lovastatin and simvastatin) and SAMAE(p = 0.0327); no significant association noted between CK and SAMAE(p = 0.5637). The SLCO1B1 rs4363657 polymorphism was significantly associated SAMAE(p < 0.0001). Conclusions: In this first pilot study of a multiethnic Malaysian population, the incidence of SAMAE was 18.6%. SAMAE were significantly higher in subjects on lovastatin compared to simvastatin. SLCO1B1 rs4363657 polymorphism was a significant risk factor for SAMAE.

4 November 2016
Verified
Journal Article
Closed access
STSubashini C Thambiah
Subashini C Thambiah
EGElizabeth George
Elizabeth George
ISIntan Nureslyna Samsudin
Intan Nureslyna Samsudin
LHLee Hoong Hong
Lee Hoong Hong
LCLing Ling Chuo
Ling Ling Chuo
MZMuhd Zanapiah Zakaria
Muhd Zanapiah Zakaria